Results 81 to 90 of about 3,123 (163)

New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin

Therapeutics and Clinical Risk Management, 2016
Janelle J Juul, Caitlin F Mullins, William J Peppard, Angela M Huang Department of Pharmacy, Froedtert & the Medical College of Wisconsin, Milwaukee, WI, USA Abstract: Dalbavancin, an intravenous glycopeptide, was approved by the US Food and Drug ...
Juul JJ, Mullins CF, Peppard WJ, Huang AM   +3 more
doaj  

Exploratory analysis of long-term suppressive therapy with dalbavancin in ventricular assist device infections caused by Staphylococcus aureus

Scientific Reports
To analyze dalbavancin’s potential for long-term suppressive therapy in patients with infected ventricular assist devices (VAD), the VAD register of Heidelberg University Hospital was searched for patients who received dalbavancin for long-term ...
Benedict Morath, Sabrina Klein, Ute Chiriac, Yvonne Müller, Lisa Koeppel, Otto Frey, Heike Lanzinger, Philipp Schlegel, Sonja Hamed, Dennis Nurjadi, Philipp Ehlermann, Matthias Karck, Anna L. Meyer   +12 more
doaj   +1 more source

Evaluating the Use of Dalbavancin for Off-Label Indications

, 2022
(1) Background: Dalbavancin is a long-acting lipoglycopeptide antibiotic approved for skin and soft-tissue infections. Post-marketing experience suggests dalbavancin is being used for off-label indications that normally require long-term intravenous (IV)
Zachary Gruss, Chris Ohl, Courtney Russ-Friedman, James Beardsley, Katherine Taylor, Tyler Stone, James Johnson, Vera Luther, John Williamson   +8 more
core   +1 more source

Dalbavancin plasma concentrations in 133 patients: a PK/PD observational study

, 2023
International audienceAbstract Objectives Limited pharmacokinetics data support dalbavancin long-term use in off-label indications and the optimal dosing regimen is debated.
Vincent Dubée, Dinh, Aurélien, Grégoire, Matthieu, Éric Senneville, Benjamin Hennart, Dailly, Eric, Gabriella Illes, Castan, Bernard, Corvec, Stéphane, Chavanet, Pascal, Albert Sotto, Jean-Philippe Talarmin, Ronan Bellouard, Illes, Gabriella, Hennart, Benjamin, Boutoille, David, de Carné, Marie-Charlotte, Talarmin, Jean-Philippe, Charles Hervochon, Aurélien Dinh, Anne-Gaëlle Leroy, David Boutoille, Éric Dailly, Bleibtreu, Alexandre, Senneville, Éric, Sotto, Albert, Matthieu Revest, Pascal Chavanet, Paul Le Turnier, Stéphane Corvec, Revest, Matthieu, Bernard Castan, Hervochon, Charles, Dubée, Vincent, Le Turnier, Paul, Alexandre Bleibtreu, Bellouard, Ronan, Delphine Allorge, Marie-Charlotte De Carné, Leroy, Anne-Gaëlle, Matthieu Gregoire, Allorge, Delphine   +41 more
core   +1 more source

Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome following Dalbavancin and Oritavancin Administration in a Patient with Osteomyelitis

Case Reports in Dermatology
Introduction: Dalbavancin and oritavancin are newer long-acting antibiotics with potent activity against gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA). To our knowledge, there have been no reported cases
Jina Bai, Emily Frech Preciado, Mary Baxter Harlow, Nina Blank   +3 more
doaj   +1 more source

Efficacy, safety, and population pharmacokinetics of a single 1500mg dose of dalbavancin for short-term therapy in patients with chronic prosthetic joint infections

Antimicrobial Agents and Chemotherapy
The efficacy, safety, and population pharmacokinetics of a single 1,500 mg dose of dalbavancin as a sequencing treatment for Gram-positive chronic prosthetic joint infections (CPJIs) have not been described.
Eva Benavent, Jaime Lora-Tamayo, Marta Ulldemolins, Paula Pons-Oltra, Matthieu Gregoire, Mikel Mancheño-Losa, Pilar Hernández-Jiménez, M. Ángeles Meléndez-Carmona, Victor Casals, Jason A. Roberts, Raul Rigo-Bonnin, Oscar Murillo   +11 more
doaj   +1 more source

Emergence of Dalbavancin Non-Susceptible Methicillin-Resistant Staphylococcus epidermidis (MRSE) in a Patient Treated With Dalbavancin prolonged therapy: Case Report, Therapeutic Drug Monitoring and Genomic Characterization

Objective: We reported stepwise evolution of a Methicillin-Resistant Staphylococcus epidermidis (MRSE) with reduced susceptibility to dalbavancin in a patient with recurrent episode of bloodstream infections (BSIs).
PEA, Federico, MOREAL, Chiara, BULFONI, Michela, CURCIO, Francesco, GIULIANO, Simone, COTRUFO, Marco, GUALANDI, Nicolo, TASCINI, Carlo, COJUTTI, PierGiorgio, GAIBANI, Paolo, LOMBARDO, Cinzia   +10 more
core   +1 more source

A Little Bit of Dalba Goes a Long Way: Dalbavancin Use in a Vulnerable Patient Population

, 2017
Background Serious staphylococcal infections require prolonged courses of intravenous (IV) antibiotics. Weekly IV dalbavancin is an alternative to more frequent IV antimicrobial dosing for homeless patients or persons who inject drugs ...
Chloe Bryson-Cahn, Steve Senter, Jeannie Chan, Robert Harrington, Shireesha Dhanireddy, Alison Beieler   +5 more
core   +1 more source

Dalbavancin for the treatment of paediatric infectious diseases

, 2016
To review the topics of interest related to the use of dalbavancin in paediatric patients. PubMed was used to search for all of the studies published over the last 15 years using the key word “dalbavancin”.
S. Bianchini, Esposito, Susanna Maria Roberta, S. Esposito   +2 more
core   +1 more source

Strategies to Stabilize Dalbavancin in Aqueous Solutions; Section-2: The Effects of 2 Hydroxypropyl-β-Cyclodextrin and Acetate Buffer with and Without Divalent Metal Ions

Pharmaceutics
Objectives: The effect of 2-hydroxpropyl-β-cyclodextrin (2HPβCD) with or without divalent metal ions (Ca2+, Mg2+, and Zn2+) on the stability of dalbavancin in acetate buffer was investigated.
Sardar M. Jakaria, David E. Budil, James Murtagh, Graham Revilla   +3 more
doaj   +1 more source